ch19 disorders associated with the immune system: aids
TRANSCRIPT
![Page 1: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/1.jpg)
Ch19
Disorders Associated
with the Immune System: AIDS
![Page 2: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/2.jpg)
Copyright © 2010 Pearson Education, Inc.
LEARNING OBJECTIVES Explain the attachment of HIV to a host cell
List two ways in which HIV avoids the host’s antibodies
Describe the stages of HIV infection
Describe the effects of HIV infection on the immune system
Describe how HIV infection is diagnosed
List the routes of HIV transmission
Identify geographic patterns of HIV transmission
List the current methods of preventing and treating HIV infection
![Page 3: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/3.jpg)
Copyright © 2010 Pearson Education, Inc.
Acquired Immunodeficiency Syndrome (AIDS)
Origin and History 1981: In US, cluster of Pneumocystis pneumonia and Kaposi's
sarcoma in young homosexual men discovered. The men showed loss of immune function.
1983: Discovery of virus causing loss of immune function.
1986: Scientists started to identify the virus with "HIV" abbreviation.
HIV is thought to have crossed the species barrier into humans in central Africa in the 1930s.
Patient who died in 1959 in Congo is the oldest known case.
Virus spread in Africa as result of urbanization. World-wide spread through modern transportation and unsafe sex.
Norwegian sailor who died in 1976 is the first known case in Western world.
![Page 4: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/4.jpg)
HIV Infection – Review from Ch 13
Fig13.19
![Page 5: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/5.jpg)
:
Th cells APCs brain cell intestinal epithelium
Pathogenesis: HIV cellular targets
![Page 6: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/6.jpg)
HIV: Retrovirus with ssRNA, RT, and envelope with gp120 spikes.
Gp120 attach to CD4 on ________ cells, M, dendritic cells.
Function of RT?
Provirus latent or directs active viron synthesis
HIV evades IS via latency, vacuoles, antigenic change
HIV Infection – AIDS is Final stage of HIV Infection
Fig 19.13
![Page 7: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/7.jpg)
HIV Attachment, Fusion, and Entry
Fig 19.13
![Page 8: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/8.jpg)
Latent vs. Active HIV Infection in CD4+ T Cells
Fig19.14b
![Page 9: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/9.jpg)
Active HIV Infection in Macrophages
Fig19.15
![Page 10: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/10.jpg)
Copyright © 2010 Pearson Education, Inc.
The Stages of HIV Infection Phase 1: Asymptomatic or chroniclymphadenopathy Phase 2: Symptomatic; early indications of immune
failure Phase 3 is AIDS: Characterized by indicator
conditions, such as: CMV, TB, Pneumocystis, toxoplasmosis, and Kaposi's sarcoma (see Table 19.5)
Phases 1 and 2 are reported as AIDS if CD4+ T cells <200 cells/µl; Phase 3 always reported as AIDS
Progression from HIV infection to AIDS: 10 y The life of an AIDS patient can be prolonged by the
proper treatment of opportunistic infections People lacking CCR5 are resistant to HIV infection
![Page 11: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/11.jpg)
Several chemokine receptors can function as viral coreceptors, but CCR5 is likely the most physiologically important. new experimental HIV drugs, called entry inhibitors
![Page 12: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/12.jpg)
The Progression of HIV Infection
Foundation Fig19.16
![Page 13: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/13.jpg)
Exposed, but not infected CCR5 mutation Effective CTLs
Long-term nonprogressors Mechanism not known
Survival with HIV Infection
![Page 14: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/14.jpg)
Pneumocystis jirovecii
![Page 15: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/15.jpg)
Copyright © 2010 Pearson Education, Inc.
Diagnostic Methods
Seroconversion takes up to 3 months
HIV antibodies detected by ELISA
HIV antigens detected by Western blotting
HIV antigens detection for diagnosis of congenital HIV infection, needle stick accidents and to monitor drug therapy: Plasma viral load tests (PCR or Western blot)
Plasma viral load (PVL) is determined by PCR or nucleic acid hybridization
![Page 16: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/16.jpg)
To be conclusive (HIV-positive), a Western Blot must have 5 horizontal stripes.
![Page 17: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/17.jpg)
![Page 18: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/18.jpg)
Copyright © 2010 Pearson Education, Inc.
HIV Transmission
HIV survives 6 h outside a cell and < 1.5 d inside a cell
Infected body fluids transmit HIV via Sexual contact Breast milk Transplacental infection of fetus Blood-contaminated needles Organ transplants Artificial insemination Blood transfusion
In developed countries, blood transfusions are not a likely source of infection anymore
![Page 19: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/19.jpg)
Copyright © 2010 Pearson Education, Inc.
AIDS Worldwide
Fig 19.17
Heterosexual intercourse (85%) Injected drug use (IDU) Women comprise 42% of infected
![Page 20: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/20.jpg)
Copyright © 2010 Pearson Education, Inc.
AIDS Prevention Condoms and sterile needles!
Health care workers use Universal Precautions: Wear gloves, gowns, masks, and goggles Do not recap needles Risk of infection from infected needlestick injury
is 0.3%
Vaccine difficulties due to Mutations Geographical clades Antibody-binding sites “hidden” Infected cells not susceptible to CTLs Proviruses Latent viruses
(2099 last phase III trial in Thailand)
See Table 19.6
![Page 21: Ch19 Disorders Associated with the Immune System: AIDS](https://reader035.vdocument.in/reader035/viewer/2022062417/55159d6d55034674578b5e0b/html5/thumbnails/21.jpg)
Copyright © 2010 Pearson Education, Inc.
AIDS Chemotherapy
Treatment has much improved with HAART Highly Active Anti-Retroviral Therapy - cocktail)
Nucleoside reverse transcriptase inhibitors(mostly nucleoside analogs, e.g.: AZT)
Non-nucleoside reverse transcriptase inhibitors Protease inhibitors Fusion inhibitors